Loading...

MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia

Print Friendly, PDF & Email

Pharma research advances in Freidrich’s Ataxia:    NEW YORK and GAINESVILLE, Fla., Jan. 13, 2020 /PRNewswire/ — The Muscular Dystrophy Association (MDA) and AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich’s ataxia (FA), today announced the award of MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance AavantiBio’s phase 2 clinical trial of a […]